DAWN Q3 2022 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

$2B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$165,000

Operating Income

-$40M

Net Income

-$38M

EPS (Diluted)

$-0.48

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$382M

Total Liabilities

$19M

Stockholders' Equity

$363M

Cash & Equivalents

$121M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$165,000	-$50,000	-230.0%
Operating Income	-$40M	-$19M	-106.3%
Net Income	-$38M	-$19M	-96.4%